Buscar
Abivax SA
ABVXAñadir a la lista de seguimiento
144.650USD
+12.090+9.12%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Abivax SA Compañía
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Información de Abivax SA
Símbolo de cotizaciónABVX
Nombre de la empresaAbivax SA
Fecha de salida a bolsaJun 26, 2015
Director ejecutivode Garidel (Marc)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
Dirección7-11 Boulevard Haussmann
CiudadPARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75009
Teléfono33153830963
Sitio Webhttps://www.abivax.com/
Símbolo de cotizaciónABVX
Fecha de salida a bolsaJun 26, 2015
Director ejecutivode Garidel (Marc)
Ejecutivos de Abivax SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Abivax SA?
Los cinco principales accionistas de Abivax SA son: Mr. Pierre Courteille
¿Cuántas instituciones poseen acciones de Abivax SA (ABVX)?
A fecha de 2026Q1, 353 instituciones poseen acciones de Abivax SA, con un valor de mercado combinado de aproximadamente 61.40M, lo que representa el 78.18% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -289711.00.